poisar

Stocks · News reference

TScan Therapeutics Announces About $4.1M In Employee-Related Charges From Strategic Reorganization, Expected To Be Substantially Complete By End Of Q4 2026

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TCRX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — TScan Therapeutics, Inc. (TCRX)

    Filed: 2026-10-16 AccNo: 0001193125-26-424198 Size: 138 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

    TCRX